Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GW9662 (2-chloro-5-nitro-N-phenylbenzamide) is a synthetic small molecule that acts as an irreversible antagonist of the peroxisome proliferator–activated receptor gamma (PPARγ). It binds covalently to the ligand-binding domain of PPARγ, thereby inhibiting its transcriptional activity. This compound is widely used in research to study PPARγ function and signaling pathways, particularly in metabolic diseases, inflammation, and cancer biology. It is not approved for clinical use and serves primarily as a pharmacological tool in experimental settings[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GW9662.